Observational studyInternational journal of chronic obstructive pulmonary disease
Symptomatic burden of COPD for patients receiving dual or triple therapy.
Observational study in International journal of chronic obstructive pulmonary disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Ensifentrine Added on to Dual Bronchodilator or Triple Therapy Demonstrates Clinically Meaningful Improvement in CAT Score in Symptomatic Patients with Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2026Trial
- Cost-effectiveness of a self-management maintenance programme following pulmonary rehabilitation: a UK randomised controlled trial for patients with chronic obstructive pulmonary disease.BMJ open respiratory research · 2025Trial
- Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).American journal of respiratory and critical care medicine · 2023Trial
- Ensifentrine in COPD patients taking long-acting bronchodilators: A pooled post-hoc analysis of the ENHANCE-1/2 studies.Chronic respiratory diseaseTrial
- Beyond Triple Therapy: Anti-Type 2 Biologic Therapies for Eosinophilic COPD and Respiratory Comorbidities - a Review of Clinical Evidence.Current allergy and asthma reports · 2026Review
- Chronic Obstructive Pulmonary Disease in Singapore: Current Perspectives on Prevalence, Disease Burden, and Treatment.International journal of chronic obstructive pulmonary disease · 2026Review
- Disease Burden and Unmet Needs in Chinese Patients with Symptomatic and Exacerbating COPD While on Triple Inhaled Therapy: A Cross-Sectional Real-World Study.International journal of chronic obstructive pulmonary disease · 2026Article
- Lung Function and Safety Outcomes in Patients With Moderate-to-Severe COPD Treated With Ensifentrine: A Pooled Analysis of the ENHANCE Trials.CHEST pulmonary · 2025Article
- Acute COPD exacerbation despite triple inhaled therapy: a molecular insight - TripleEx study.Respiratory research · 2025Observational
- Clinical Burden of People with Symptomatic and Exacerbating COPD While on Triple Inhaled Therapy.Journal of clinical medicine · 2025Article
- Patient Burden and Insights in COPD: A Survey Analysis.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2025Article
- Phosphodiesterase Inhibition as a Therapeutic Strategy for Chronic Obstructive Pulmonary Disease: Where We Have Been and What Lies Ahead.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2025Article
- Single-Inhaler Triple Therapy in Primary Care Across Europe: Expert Panel Consensus on the Consequences of Payer-Driven Access Rules and Call to Action.International journal of chronic obstructive pulmonary disease · 2025Review
- The effectiveness and value of ensifentrine for the treatment of chronic obstructive pulmonary disease.Journal of managed care & specialty pharmacy · 2024Article
- Which Endoscopic Procedure to Use and in What Patient? Valves, Coils, Foam, and Heat in COPD and Asthma.Pulmonary therapy · 2023Review
- Patients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy.International journal of chronic obstructive pulmonary disease · 2022Observational
- Cigarette smoke-induced lung inflammation in COPD mediated via CCR1/JAK/STAT /NF-κB pathway.Aging · 2020Article
- Patient-Reported Outcomes (PROs) in COPD Clinical Trials: Trends and Gaps.International journal of chronic obstructive pulmonary disease · 2020Review
- Defining severe obstructive lung disease in the biologic era: an endotype-based approach.The European respiratory journal · 2019Review
- Opioids for breathlessness: psychological and neural factors influencing response variability.The European respiratory journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCOPD is associated with a large disease burden. The use of dual (two maintenance treatments) and triple (combination of any three treatments) therapy has shown efficacy for symptom relief; however, some patients with COPD remain symptomatic despite these therapies. This study assessed the scope and magnitude of the symptomatic burden for patients with COPD receiving dual or triple therapy. PATIENTS AND
methodsCross-sectional data from three Adelphi COPD surveys (2013-2016) conducted in the USA, Europe, Japan, and China were analyzed for patients with COPD and forced expiratory volume in 1 second ≤65% receiving dual or triple therapy for ≥3 months. Physicians completed clinical and disease characteristic forms for identified patients. Corresponding patients completed questionnaires that included validated survey instruments to assess adherence and symptom impact. Descriptive statistics are reported.
resultsOur analysis included 690 patients (mean age 68.2 years; 73.3% male); 41.4% and 58.6% were receiving dual and triple therapy, respectively. Most patients had dyspnea with substantial disability (modified Medical Research Council dyspnea scale rating ≥2, 56.3%; large health status impairment from symptoms, COPD Assessment Test score >20, 64.4%). A large symptom burden was observed, even for patients highly adherent to treatment (Morisky Medication Adherence Scale 8, 30.3% [185/612]), of whom 62.1% still had a COPD Assessment Test score >20. Sensitivity analyses of patients regardless of their forced expiratory volume in 1 second status and of those receiving treatment for >6 months both reported similar results.
conclusionAlthough patients who consult their physicians more frequently than average may be overrepresented because of the observational design of this study, we report that unmet needs remain for patients with COPD, despite the use of dual or triple therapy. A percentage of patients with COPD reported major symptom burden affecting their daily living and causing a large impairment in the health status, regardless of treatment adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.